Literature DB >> 14716069

Severe bronchiectasis.

Brian M Morrissey1, Samuel J Evans.   

Abstract

Bronchiectasis is primarily the result of airway injury and remodeling attributable to recurrent or chronic inflammation and infection. The underlying etiologies include autoimmune diseases, severe infections, genetic abnormalities, and acquired disorders. Recurrent airway inflammation and infection may also be the result of allergic or immunodeficiency states such as allergic bronchopulmonary mycoses or HIV/AIDS. Bronchiectasis should be included in the differentiation diagnosis of any patient with chronic respiratory complaints such as cough and sputum production. Early clinical manifestations may be subtle. Hallmarks of severe bronchiectasis include fetid breath, chronic cough, and sputum production. The associated chronic respiratory infections and airway sepsis are punctuated by episodes of acute exacerbation. Prompt recognition and treatment of bronchiectasis may allow for prevention of disease progression and irreversible loss of lung function. This review of severe non-cystic fibrosis bronchiectasis describes the current pathophysiology, clinical presentations, and management of bronchiectasis. We review how impaired airway clearance and the inability to resolve infection and inflammation creates a vicious cycle of recurrent injury. The common clinical features of bronchiectasis and findings are presented and illustrated by radiographic images. The common species and significance of various organisms often recovered from the distal airways including: tuberculous and environmental mycobacteria, aspergillus, and bacteria such as Pseudomonas aeruginosa will be covered. Management strategies including sputum surveillance, sputum clearance, antimicrobial therapy including antifungal and antimyobacterial agents as well as the evidence for the use of inhalational and anti-inflammatory therapies such as corticosteroids are also discussed. Recommendations for the work-up and therapy of complications including hemoptysis and respiratory failure are presented.

Entities:  

Mesh:

Year:  2003        PMID: 14716069     DOI: 10.1385/CRIAI:25:3:233

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  134 in total

Review 1.  Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases.

Authors:  Kevin W Garey; Anita Alwani; Larry H Danziger; Israel Rubinstein
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

2.  Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis.

Authors:  F Salez; A Brichet; S Desurmont; J M Grosbois; B Wallaert; A B Tonnel
Journal:  Chest       Date:  1999-12       Impact factor: 9.410

3.  Comparison of thin section computed tomography with bronchography for identifying bronchiectatic segments in patients with chronic sputum production.

Authors:  N C Munro; J C Cooke; D C Currie; B Strickland; P J Cole
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

4.  Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis.

Authors:  E Marchand; C Verellen-Dumoulin; M Mairesse; L Delaunois; P Brancaleone; J F Rahier; O Vandenplas
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

5.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.

Authors:  A E O'Donnell; A F Barker; J S Ilowite; R B Fick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

6.  Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations.

Authors:  J H Huang; P N Kao; V Adi; S J Ruoss
Journal:  Chest       Date:  1999-04       Impact factor: 9.410

7.  Bronchiectasis: an orphan disease with a poorly-understood prognosis.

Authors:  T Keistinen; O Säynäjäkangas; T Tuuponen; S L Kivelä
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

8.  Diffuse panbronchiolitis in the United States.

Authors:  J E Fitzgerald; T E King; D A Lynch; R M Tuder; M I Schwarz
Journal:  Am J Respir Crit Care Med       Date:  1996-08       Impact factor: 21.405

9.  The response of patients with purulent bronchiectasis to antibiotics for four months.

Authors:  S L Hill; D Burnett; K A Hewetson; R A Stockley
Journal:  Q J Med       Date:  1988-02

10.  Large airway disease associated with inflammatory bowel disease.

Authors:  A Spira; R Grossman; M Balter
Journal:  Chest       Date:  1998-06       Impact factor: 9.410

View more
  1 in total

1.  Diagnostic yield of bronchial washing fluid analysis for hemoptysis in patients with bronchiectasis.

Authors:  Ju-Hee Park; Soo Jung Kim; Ae-Ra Lee; Jung-Kyu Lee; Junghyun Kim; Hyo-Jeong Lim; Young Jae Cho; Jong Sun Park; Ho Il Yoon; Jae-Ho Lee; Choon-Taek Lee; Sei Won Lee
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.